Lupin Receives Approval for Tavaborole Topical Solution

Global pharma major Lupin Limited (Lupin) today announced that it has received approval for its Tavaborole Topical Solution, 5%, from the United States Food and Drug Administration, to market a generic equivalent of Kerydin® Topical Solution, 5%, of Anacor Pharmaceuticals, Inc. The product will be manufactured at Lupin's facility in Pithampur, India.

Tavaborole Topical Solution, 5%, is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.

Tavaborole Topical Solution (RLD: Kerydin®) had estimated annual sales of USD 76 million in the U.S. (IQVIA MAT December 2020).

Shares of LUPIN LTD. was last trading in BSE at Rs.1059.35 as compared to the previous close of Rs. 1069.65. The total number of shares traded during the day was 78237 in over 2653 trades.

The stock hit an intraday high of Rs. 1079.45 and intraday low of 1053.35. The net turnover during the day was Rs. 83514038.

Source : Equity Bulls

Keywords